BioPharm International Celebrates 25 Years
Throughout BioPharm International's 25th Anniversary Year, 2012, we will be rewinding to articles published in the journal's first volume to see where and how technologies have changed in the past couple of decades as well as what the industry may look forward to.
Retrospective: Separations Technology
The 1988 article identified the major challenges with membrane technology as "considerable fouling from solids in the solution that clog the membrane, molecular weight and pore size specifications that often are inaccurate because of the inexact process of membrane fabrication, and vulnerability of membranes to degradation after repeated sanitization steps" (1). BioPharm International talked to Michiel E. Ultee, chief scientific officer at Laureate Biopharmaceutical Services and a member of Biopharm International's Editorial Advisory Board, about what's changed since the article's publication.
Read the original article. Read the 25th anniversary interview. Listen to the podcast interview. (Published January 2012)
More to come each month throughout 2012!
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
